TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00608595
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
Study: NCT02492841
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
Study: NCT02492841
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
Study: NCT01886560
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
Study: NCT01353846
Drug: Agonist GnRH; estradiol Valerate; progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
Study: NCT00755378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02096588
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
Study: NCT00690482
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, twice daily
Study: NCT00690482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral tablet, twice daily
Study: NCT01930175
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01930175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03508869
Drug: Mirvaso® (brimonidine) topical gel, 0.33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
Study: NCT03508869
Drug: Dysport®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
Study: NCT03508869
Drug: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
Study: NCT02549846
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
Study: NCT01886560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets placebo one PO per day for 12 weeks
Study: NCT00240617
Drug: sumatriptan succinate/naproxen sodium
Normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator
Study: NCT00240617
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match
Study: NCT03199313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Sutezolid placebo
Study: NCT01660022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01660022
Drug: 300 mg OZ439 single oral dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg OZ439 oral suspension single dose
Study: NCT01660022
Drug: 800 mg OZ439 single oral dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg OZ439 oral suspension single dose
Study: NCT01380249
Drug: PDM08
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
Study: NCT03630094
Drug: FEP-ZID
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
Study: NCT00141141
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03695055
Drug: Maintenance therapy post-HSCT
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab vs DPP/DCEP-G vs observation
Study: NCT00500890
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g/m\^2 by vein, Over 1 Hour x 2 Days
Study: NCT00922324
Drug: STP206 or vehicle control
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
Study: NCT04184999
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ophthalmic steroid drop
Study: NCT00280176
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 225mg/m2 given weekly, up to 6 weeks
Study: NCT03020719
Drug: Oral Glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glutathione oral powder
Study: NCT03020719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral powder
Study: NCT04509999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as formulated by mouth daily
Study: NCT02870036
Drug: Simmitecan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02870036
Drug: 5-fluorouracil and Leucovorin Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02521181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
Study: NCT01297816
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg,BD, fo three month
Study: NCT01297816
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg
Study: NCT02459418
Drug: Afolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
Study: NCT00109837
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
Study: NCT00109837
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
Study: NCT00109837
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC \< 3,000
Study: NCT00109837
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
Study: NCT00109837
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
Study: NCT00836147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
Study: NCT00982501
Drug: WS® 1442 900 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00982501
Drug: WS® 1442 1800 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00955552
Drug: Glucosamine sulphate and chondroitin sulphate association
Approvals — FDA: no, EMA: no, PMDA: no
Description: glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
Study: NCT00955552
Drug: Cosamin DS® (Nutramax)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
Study: NCT00128466
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00128466
Drug: streptomycin
Normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00614926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
Study: NCT01188265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA plus placebo
Study: NCT01518595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pts. will receive placebo for 3 months
Study: NCT01529307
Drug: TAS266
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS266 IV infusions given weekly
Study: NCT00491907
Drug: folic acid 5mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00317642
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (sodium Chloride) 1-hour IV infusion
Study: NCT01546142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT02975037
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 250 mg PO
Study: NCT00556491
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
Study: NCT00556491
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
Study: NCT00809965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet twice daily
Study: NCT00809965
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03580564
Drug: KL-A167
Approvals — FDA: no, EMA: no, PMDA: no
Description: KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Study: NCT00882206
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
Study: NCT00882206
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: \*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
Study: NCT00705120
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01826461
Drug: PDI-192
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01826461
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00505648
Drug: Tegeline®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
Study: NCT01164215
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
Study: NCT01164215
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
Study: NCT01028911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
Study: NCT00284804
Drug: MDX-060
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
Study: NCT01077817
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02593396
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
Study: NCT04344457
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg PO TID 14 Days
Study: NCT04344457
Drug: Zithromax Oral Product
Normalized name: Zithromax Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg PO QD 3 Days
Study: NCT04273282
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
Study: NCT00368563
Drug: Helioblock SX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005086
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01010750
Drug: LDX Placebo + MAS-IR Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
Study: NCT00667004
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT02573857
Drug: DSM265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension from bulk powder
Study: NCT01652976
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
Study: NCT00295685
Drug: Antacids
Normalized name: ANTACIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02726646
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
Study: NCT02726646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The application of 1 mg of microspheres placebo
Study: NCT02605213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for control Group of primary sclerosing vhlangitis
Study: NCT00860743
Drug: Antioxidant cocktail
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
Study: NCT00141661
Drug: PF-04494700 - High Dose Arm
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg loading dose for 6 days, followed by 20 mg daily
Study: NCT06193031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
Study: NCT00904748
Drug: Viagra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
Study: NCT01946984
Drug: Diclofenac hydroxyethylpyrrolidine
Normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01946984
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02622685
Drug: DWP10292
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DWP10292 tablets, oral administration, multiple administration
Study: NCT02622685
Drug: DWP10292 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, oral administration, multiple administrations
Study: NCT02622685
Drug: UDCA Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, oral administration, multiple administrations
Study: NCT01908894
Drug: BIOD-123
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00789165
Drug: no therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy; this is not a placebo-controlled trial
Study: NCT00455026
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target effect site concentration during induction
Study: NCT01048463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
Study: NCT01048463
Drug: HDEPA
Normalized name: Hydroxyethyl Diethylenetriamine Pentaacetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
Study: NCT01048463
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
Study: NCT00161681
Drug: Levonorgestrel/Ethinyl Estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01961388
Drug: Bay G5421 Glucobay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, dosage of Acarbose as per the directions of treating physician
Study: NCT01202877
Drug: PKC412
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
Study: NCT01295086
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/² continuously
Study: NCT02341521
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally for 8 days
Study: NCT01351350
Drug: MLN0128
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN0128 capsules
Study: NCT00186823
Drug: TBI, systemic chemotherapy and antibodies as follows:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
Study: NCT01684878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
Study: NCT00938145
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
Study: NCT00642941
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Study: NCT03376620
Drug: 1,4-Diaminobutane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application to surgical breast scars of 1,4 diaminobutane on the active side
Study: NCT03376620
Drug: 10% Urea cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application to surgical breast scars of 10% Urea cream on the sham side
Study: NCT03221231
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily, placebo
Study: NCT00304707
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02355756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01255657
Drug: ABT-806
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-806 will be administered by intravenous infusion.
Study: NCT02903238
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose capsule
Study: NCT05209906
Drug: Fentanyl Buccal Soluble Film
Normalized name: fentanyl Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
Study: NCT02985879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.